Lexaria Bioscience (LEXX) Net Cash Flow (2010 - 2026)
Lexaria Bioscience (LEXX) posted Net Cash Flow of -$1.7 million for Q2 2026, down 301.16% sequentially from $826273.0 in Q1 2026, and up 13.18% YoY from -$1.5 million in Q2 2025.
Lexaria Bioscience (LEXX) Net Cash Flow (2010 - 2026) Analysis & Trends
Lexaria Bioscience has reported Net Cash Flow for 17 years, with the latest figure at -$1.7 million in Q2 2026.
- Quarterly Net Cash Flow rose 13.18% year-over-year to -$1.7 million in Q2 2026, while the trailing twelve-month figure through May 2026 was -$1.2 million (up 69.77% YoY) and the FY2025 annual result came in at -$4.6 million, down 189.93% from the prior year.
- Net Cash Flow slipped to -$1.7 million in Q2 2026 per LEXX's latest filing, from $826273.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $3.8 million in Q2 2024 and troughed at -$2.8 million in Q3 2025.
- A 5-year average of -$342266.4 and a median of -$1.3 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow soared 3570.48% in 2024, then plunged 154.54% in 2025.
- Over 5 years, Net Cash Flow stood at -$1.3 million in 2022, then jumped by 146.69% to $597691.0 in 2023, then soared by 164.61% to $1.6 million in 2024, then jumped by 57.12% to $2.5 million in 2025, then tumbled by 166.89% to -$1.7 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$1.7 million, $826273.0, and $2.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | -1.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -1.66 Mn |
| May 31, 2026 | -1.66 Mn |
| Feb 28, 2026 | 826,273.00 |
| Feb 28, 2026 | 826,273.00 |
| Nov 30, 2025 | 2.48 Mn |
| Nov 30, 2025 | 2.48 Mn |
| Aug 31, 2025 | -2.80 Mn |
| Aug 31, 2025 | -2.80 Mn |
| May 31, 2025 | -1.91 Mn |
| May 31, 2025 | -1.91 Mn |
| Feb 28, 2025 | -1.51 Mn |
| Feb 28, 2025 | -1.51 Mn |
| Nov 30, 2024 | 1.58 Mn |
| Nov 30, 2024 | 1.58 Mn |
| Aug 31, 2024 | -1.96 Mn |
| Aug 31, 2024 | -1.96 Mn |
| May 31, 2024 | 3.75 Mn |
| May 31, 2024 | 3.75 Mn |
| Feb 29, 2024 | 2.78 Mn |
| Feb 29, 2024 | 2.78 Mn |